Sunday, March 25,2007

Hilton New Orleans Riverside

New Orleans , Louisiana

Grand Ballroom A

7:00 PM—7:30 PM    Registration and Dinner

7:30 PM—9:00 PM    General Session

 Program Agenda

7:00 PM  Registration and Dinner

7:30 PM  CME Overview

7:35 PM  Program Introduction

7:45 PM  CVD Continuum: Indetifying the Causes of CHF      Richard Shannon.MD

8:05 PM  Treatment Outcomes with Drugs for CHF          Paul J.Hauptman. MD

8:25 PM  Treatment Outcomes of Devices for CHF    Prakash Deedwania. MD. FACC. FAHA

8:45 PM  Question and Answer Session

9:00 PM  Program Adjourns

Program Chair

Richard Shannon.MD: Professor of Medicine The Hospital of the University of Pennsylvania Philadephia,Pennsylvania

Faculty

Prakash Deedwania,MD,FACC, FAHA

Chief. Cardiology Division, Director, Cardiovascular Research University of California, San Francisco, San Francisco, California Clinical Professor of Medicine Stanford University Palo Alto, California

Paul J.Hauptman, MD

Professor of Medicine Director, Heart Failure and Transplant Saint Louis University School of Medicine St. Louis, Missouri

Program Overview

This program will feature didactic lectures and faculty debates about the identification, prevention,and treatment of heart failure. Using a case-based format, the faculty will look at both devices and drugs to identify optimal management plans to increase the level of care of patients with heart failure.

Target Audience

This symposium has been developed to meet the educational needs of cardiologists and other healthcare providers who are interested in raising the level of care of their patients with hypertension.

Learning Objective

At the conclusion of this activity, participants should be able to:

l         Descirbe the mechanism of action differences between therapies for the management of CHF

l         Compare the morbidity and mortality rates of different interventions for the treatment of CHF

l         Discuss the recent clinical trials on the long-term use of –blockers and the eviderce of other therapies on progression of ventricular function and symptoms of CHF

Faculty Disclosure

In accordance with disclosure polictes of SUNY Upstate Medicine University and to conform with the ACCME and US Food and Drug Adiministration guidelines, all faculty are required to disclose to the activity participants : 1) the existence of any financial interest or other relationships with the manufacturers of any commercial products or providers of commercial services that relate to the content of their presentation/material, or the commercial contributors of this activity that could be perceived as a real or apparent conflict of interest: and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

Faculty disclosures will be available during the activity.

Accreditation

This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of SUNY Upstate Medical University and Procom. SUNY Upstate Medical University is ACCREDITED BY THE ACCME to provide continuing medical education for physicians.

Credit Designation

SUNY Upstate Medical University designates this educational activity for a maximum of 1.5 AMA PRA Category 1 Credits^TM should only claim credit commensurate with the extent of their participation in the activity.

Title IX and American Disabilities Act (ADA)

The State University of New York (SUNY) Upstate Medical University provides equal opportunities in employment and programming, including Title IX requirements. SUNY fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity has a special request, please call (877)224-5436